Recursion Pharmaceuticals, Inc. (RXRX) Stock Forecast
RXRX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.57 / 5 from 7 analysts
- Price target
- $7.32 average of analyst targets
- Upside to target
- +111.2% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.24
- 52-week range
- $2.84 – $6.68
RXRX analyst ratings
7 analystsNumber of analysts at each rating.
RXRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RXRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.25 | −$0.20 | −$0.36 | +36.4% | 6 |
| Current fiscal year (2026) | −$0.93 | −$0.99 | −$0.87 | −$1.44 | +35.7% | 7 |
| Next fiscal year (2027) | −$0.87 | −$1.04 | −$0.68 | −$0.93 | +6.0% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RXRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $14.8M | $8.3M | $30.2M | +186.2% | 7 |
| Current fiscal year (2026) | $41.8M | $29.0M | $72.0M | −44.0% | 8 |
| Next fiscal year (2027) | $53.0M | $20.7M | $110.0M | +26.9% | 8 |
RXRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RXRX revenue: reported and forecast
RXRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.23 | −$0.23 | −$0.23 | −$0.23 | −0.5% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.92 | −$0.92 | −$0.92 | −$0.93 | −$0.93 | +0.8% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.94 | −$0.88 | −$0.89 | −$0.90 | −$0.87 | −7.5% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RXRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RXRX beat in 6 of 12.
What analysts expect from RXRX
7 analysts cover Recursion Pharmaceuticals; their consensus rating is buy (3.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.32, 111.2% above the latest close of $3.46. Analysts expect earnings of −$0.93 per share for 2026, +35.7% from a year earlier. For 2027 the average estimate is −$0.87 per share on revenue of $53.0 million. Recursion Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: RXRX income statement, RXRX key metrics, RXRX chart. See the RXRX stock overview for the latest quote and news.
RXRX forecast FAQ
What is Recursion Pharmaceuticals's price target?
The average analyst price target for Recursion Pharmaceuticals is $7.32, 111.2% above the latest close of $3.46.
Is Recursion Pharmaceuticals a buy, hold or sell?
Of 7 analysts covering Recursion Pharmaceuticals, 1 rate it a strong buy, 2 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Recursion Pharmaceuticals's EPS forecast?
Analysts forecast −$0.93 per share for 2026 (range −$0.99 to −$0.87); for 2027 the estimate is −$0.87.
What is Recursion Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $41.8 million, growth of −44.0%; for 2027 it is $53.0 million.
When does Recursion Pharmaceuticals report earnings?
Recursion Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $-0.24.
Does Recursion Pharmaceuticals usually beat earnings estimates?
Recursion Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.